Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

United Therapeutics Corporation - Common Stock (NQ:UTHR)

496.00 -5.27 (-1.05%)
Streaming Delayed Price Updated: 9:40 AM EDT, Aug 14, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about United Therapeutics Corporation - Common Stock

< Previous 1 2
...
7 8 9 10 11 12 13 14 15
...
17 18 Next >
News headline image
United Therapeutics Corporation Announces Election of Jan Malcolm to its Board of Directors
From United Therapeutics Corporation
Via Business Wire
News headline image
When you look at NASDAQ:UTHR, it's hard to ignore the strong fundamentals, especially considering its likely undervaluation. ↗
UNITED THERAPEUTICS CORP (NASDAQ:UTHR) is a prime example of a stock that offers more than what meets the eye in terms of fundamentals. 
Via Chartmill
News headline image
Arcellx Stock Earns Relative Strength Rating Upgrade ↗
One key metric to look for in a stock is an 80-plus Relative Strength Rating. Arcellx stock cleared that benchmark Friday, jumping to 83. 
Via Investor's Business Daily
News headline image
The 3 Best Medical Device Stocks to Buy in June 2024 ↗
Medical devices are at the forefront of the digitalization of medicine. making these the three best medical device stocks to buy. 
Via InvestorPlace
News headline image
Intra-Cellular Therapies Stock Scores RS Rating Upgrade To 87 ↗
Intra-Cellular Therapies sees its Relative Strength Rating enter the 80-plus level. 
Via Investor's Business Daily
News headline image
Deep Dive Into United Therapeutics Stock: Analyst Perspectives (5 Ratings) ↗
 
Via Benzinga
News headline image
Expert Ratings For United Therapeutics ↗
 
Via Benzinga
News headline image
The Latest Analyst Ratings For United Therapeutics ↗
 
Via Benzinga
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
Neurocrine Biosciences Stock Tops Milestone Amid New Drug Plans ↗
Neurocrine Biosciences has long been known for its blockbuster drug Ingrezza. It's diversifying, developing multiple drugs in related areas. 
Via Investor's Business Daily
News headline image
Madrigal Pharmaceuticals Stock Earns RS Rating Upgrade ↗
On Wednesday, Madrigal Pharmaceuticals stock earned an upgrade to its Relative Strength (RS) Rating, from 74 to 90. 
Via Investor's Business Daily
News headline image
Krystal Biotech Stock Sees RS Rating Jump To 91 ↗
On Tuesday, Krystal Biotech stock cleared a key technical benchmark, seeing its Relative Strength Rating jump to 91 from 88. 
Via Investor's Business Daily
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
Halozyme Therapeutics Scores RS Rating Jump To 91 ↗
On Friday, Halozyme Therapeutics stock earned an upgrade to its Relative Strength (RS) Rating, from 80 to 91. 
Via Investor's Business Daily
News headline image
For those who appreciate value investing, NASDAQ:UTHR is a compelling option with its solid fundamentals. ↗
Investors should take notice ofUNITED THERAPEUTICS CORP (NASDAQ:UTHR)—it offers a great deal for the fundamentals it presents. 
Via Chartmill
News headline image
United Therapeutics Corporation to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
From United Therapeutics Corporation
Via Business Wire
News headline image
The 3 Most Undervalued Healthcare Stocks to Buy in June 2024 ↗
Seeking discounts in relevant places makes sense and there are few arenas more compelling than undervalued healthcare stocks. 
Via InvestorPlace
News headline image
Liquidia Stock Surges After Winning Patent Battle Vs. United Therapeutics ↗
Liquidia stock retook its 50-day line Monday on a U.S. judge's ruling on a patent dispute with fellow biotech company United Therapeutics. 
Via Investor's Business Daily
Topics Intellectual Property
News headline image
7 Biotech Stocks That Could Breathe New Life Into Your Portfolio ↗
Thanks to the underlying pertinence, these established biotech stocks to buy offer confidence to investors facing tricky market conditions. 
Via InvestorPlace
News headline image
Halozyme Therapeutics Stock Earns IBD Stock Rating Upgrade, Hitting 80-Plus RS Rating ↗
On Thursday, biotech Halozyme Therapeutics stock had its Relative Strength (RS) Rating upgraded to 84, up from 80 a day earlier. 
Via Investor's Business Daily
News headline image
NASDAQ:UTHR is a prime example of a stock that offers more than what meets the eye in terms of fundamentals. ↗
UNITED THERAPEUTICS CORP (NASDAQ:UTHR), an undervalued stock with good fundamentals. 
Via Chartmill
News headline image
Catalyst Pharmaceuticals Stock Clears Technical Benchmark With 83 RS Rating ↗
On Tuesday, Catalyst Pharmaceuticals stock hit a key technical milestone, with its Relative Strength Rating climbing to 83 from 79. 
Via Investor's Business Daily
News headline image
3 Biotech Stocks to Double Your Money in the Next 24 Months ↗
The biotech sector offers significant potential for growth. These 3 biotech stocks to double your money are noteworthy candidates. 
Via InvestorPlace
News headline image
Lung Disease-Focused United Therapeutics Says It Is A Compelling Investment Opportunity ↗
United Therapeutics impresses with record-breaking Q1 results. Revenue soars 34% Y/Y to $677.7 million, EPS jumps to $6.17. Tyvaso leads the charge with a 56% revenue surge. 
Via Benzinga
News headline image
UTHR Stock Earnings: United Therapeutics Beats EPS, Beats Revenue for Q1 2024 ↗
UTHR stock results show that United Therapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
News headline image
Powell Industries Posts Upbeat Results, Joins A10 Networks, Garmin, DuPont And Other Big Stocks Moving Higher On Wednesday ↗
 
Via Benzinga
News headline image
United Therapeutics Corporation Reports First Quarter 2024 Financial Results
From United Therapeutics Corporation
Via Business Wire
News headline image
CORRECTING and REPLACING PHOTO United Therapeutics Announces World’s First Successful Xenothymokidney Transplant
From United Therapeutics Corporation
Via Business Wire
News headline image
United Therapeutics Corporation to Report First Quarter 2024 Financial Results Before the Market Opens on Wednesday, May 1, 2024
From United Therapeutics Corporation
Via Business Wire
News headline image
NASDAQ:UTHR stands out as a stock that provides good value for the fundamentals it showcases. ↗
Despite its impressive fundamentals, UNITED THERAPEUTICS CORP (NASDAQ:UTHR) remains undervalued. 
Via Chartmill
< Previous 1 2
...
7 8 9 10 11 12 13 14 15
...
17 18 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.